Jove
Visualize
Contact Us

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Epigenetic Regulation01:46

Epigenetic Regulation

31.1K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
31.1K
Master Transcription Regulators02:23

Master Transcription Regulators

6.9K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
6.9K
Abnormal Proliferation02:23

Abnormal Proliferation

4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
MicroRNAs01:22

MicroRNAs

21.3K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.3K
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Rna M6a Methylation Regulator Expression In Castration-resistant Prostate Cancer Progression And Its Genetic Associations.
  1. Home
  3. Rna M6a Methylation Regulator Expression In Castration-resistant Prostate Cancer Progression And Its Genetic Associations.

Related Experiment Video

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.8K

RNA m6a Methylation Regulator Expression in Castration-Resistant Prostate Cancer Progression and Its Genetic

Chamikara Liyanage1,2, Achala Fernando1,2, Audrey Chamberlain1,2

  • 1School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4059, Australia.

Cancers
|April 13, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

N6-methyladenosine (m6A) regulators are altered in prostate cancer (PCa) progression. Understanding these m6A changes can improve PCa diagnosis and prognosis.

Keywords:
androgen-targeted therapycastration-resistant prostate cancerm6A methylationprostate cancersingle-nucleotide polymorphisms

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.9K
MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

24.5K

Related Experiment Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.8K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.9K
MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

24.5K

Area of Science:

  • Epitranscriptomics
  • Cancer Biology
  • Molecular Oncology

Background:

  • N6-methyladenosine (m6A) methylation is a key epitranscriptomic modification influencing gene expression.
  • m6A regulators are implicated in tumorigenesis, with research focused on primary prostate cancer (PCa).
  • The role of m6A regulators in PCa progression to castration-resistant prostate cancer (CRPC) remains underexplored.

Purpose of the Study:

  • To investigate the dynamic expression patterns of m6A regulators during PCa progression.
  • To identify m6A regulators associated with PCa survival and risk loci.

Main Methods:

  • Utilized sequential window acquisition of all theoretical mass spectra (SWATH-MS) and RNAseq analysis.
  • Profiled 27 m6A regulators in hormone-dependent and -independent PCa cell lines.
  • Performed association analysis with The Cancer Genome Atlas (TCGA) data for risk loci.

    • Main Results:

    • Distinct clustering of m6A regulator expression between PCa tumors and normal prostate tissues.
    • Upregulation of METTL3, RBM15B, HNRNAPA2B1 and downregulation of ZC3H13, NUDT21, FTO observed in high-grade PCa.
    • Identified six m6A regulators linked to PCa survival and significant expression quantitative trait loci near WTAP, HNRNPA2B1, and FTO.

    Conclusions:

    • m6A regulator expression is significantly altered during PCa progression.
    • Genetic variations near specific m6A regulator genes are associated with PCa risk.
    • Prognostic stratification using m6A regulator expression may enhance PCa diagnosis and treatment strategies.